Friday 6 November 2026
Export RVTY’s income statement to Excel — free account
Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
150.97
8.46
−5.31%
Follow RVTY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
72.80 | 52.98 | 41.92 | 46.51 |
+8 more quarters Free account |
P/S ratio |
5.80 | 4.26 | 3.38 | 3.95 | |
P/FCF ratio |
28.55 | 21.97 | 19.73 | 22.35 | |
P/Operating CF |
102.34 | 64.68 | 85.04 | 61.97 | |
P/B ratio |
2.36 | 1.72 | 1.36 | 1.56 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.69 | 5.01 | 4.19 | 4.75 | |
EV/EBITDA |
25.36 | 18.82 | 15.62 | 17.71 | |
EV/Operating CF |
30.00 | 23.26 | 21.31 | 23.29 | |
EV/FCF |
32.93 | 25.83 | 24.46 | 26.91 | |
Quick Ratio |
1.82 | 1.36 | 1.25 | 1.25 | |
Current Ratio |
2.65 | 1.80 | 1.72 | 1.68 | |
Net Debt/EBITDA |
0.00 | 11.33 | 12.89 | 10.66 | |
Debt/Assets |
22.92% | 26.61% | 26.74% | 26.46% | |
Debt/Equity |
0.36 | 0.44 | 0.45 | 0.44 | |
Asset Turnover |
0.25 | 0.24 | 0.24 | 0.23 | |
Operating CF/Net income |
2.68 | 3.70 | 2.83 | 1.85 | |
Capex/Depreciation |
(0.14) | (0.08) | (0.10) | (0.19) | |
Interest Coverage |
4.57 | 3.46 | 2.93 | 5.54 | |
Research and Development Expense of Revenue |
6.60% | 6.71% | 8.14% | 7.54% | |
Selling, General and Administrative Expense of Revenue |
37.77% | 38.18% | 35.70% | 32.61% | |
Intangible Assets out of Total Assets |
0.76 | 0.73 | 0.74 | 0.74 | |
Share Based Compensation of Revenue |
1.34% | 1.47% | 1.23% | (0.53%) | |
Graham Net Nets |
(0.14) | (0.20) | (0.27) | (0.24) | |
Graham Number |
— | 55.33 | 54.95 | 53.96 | |
Earnings Yield |
1.37% | 1.89% | 2.39% | 2.15% | |
Free Cash Flow Yield |
3.50% | 4.55% | 5.07% | 4.47% | |
Revenue per Share |
0.00 | 6.54 | 6.36 | 6.62 | |
Operating CF per Share |
0.00 | 1.72 | 1.03 | 1.56 | |
Capex per Share |
0.00 | (0.07) | (0.10) | (0.17) | |
Free Cash Flow per Share |
0.00 | 1.65 | 0.93 | 1.39 | |
Cash per Share |
0.00 | 9.17 | 7.69 | 7.89 | |
Shareholders Equity per Share |
0.00 | 64.78 | 64.22 | 62.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 64.78 | 64.22 | 62.21 | |
Free Cash Flow |
152.36 | 183.91 | 104.46 | 161.79 | |
Working Capital |
1,159.91 | 1,021.36 | 889.67 | 908.50 | |
Capital Expenditures |
(14.35) | (8.04) | (10.77) | (20.17) | |
Net Current Asset Value |
(2,357.85) | (2,519.35) | (2,685.53) | (2,678.30) | |
EV/EBIT |
52.87 | 40.68 | 33.71 | 38.07 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.03 | |
Price to Operating Income |
45.85 | 34.60 | 27.20 | 31.62 | |
| Other line items | |||||
Average Receivables |
683.79 | 685.16 | 654.40 | 688.54 | |
Average Payables |
169.54 | 171.95 | 173.88 | 176.46 | |
Average Inventory |
384.38 | 383.48 | 384.41 | 373.54 | |
Average Assets |
11,814.65 | 12,204.31 | 12,178.66 | 12,280.45 | |
Average Common Equity |
— | 7,392.46 | 7,409.93 | 7,458.62 |
Columns are period end dates · fundamentals updated 5 Nov 2026